ENDRA Life Sciences Inc.NDRA
Price (close)
$5.93
Market cap
$8.9M
P/E
—
Revenue (TTM)
—
Net income
-$5.9M
Dividend yield
—
1-year total return
21.0%
Net margin
—
Revenue growth
—
Debt / equity
—
What ENDRA Life Sciences Inc. does.
corporation in 2007. We are developing a next-generation enhanced ultrasound technology platform—Thermo- Acoustic Enhanced
commercialization of TAEUS is a solution for the assessment of liver fat, a key biomarker associated with metabolic diseases,
our vision, purpose, and go-to-market strategy with respect to TAEUS in response to evolving market conditions and development
Revenue and profit, by fiscal year.
| Fiscal year | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| Revenue | $0 | — | — | — | — | — |
| Net income | -$11.7M | -$11.2M | -$13.2M | -$10.1M | -$11.5M | -$7.0M |
| Free cash flow | -$10.8M | -$11.2M | -$13.0M | -$9.6M | -$7.4M | -$5.2M |
More on NDRA.
- ENDRA Life Sciences Inc. summary
- ENDRA Life Sciences Inc. financial statements
- ENDRA Life Sciences Inc. key metrics
- ENDRA Life Sciences Inc. health scores and style box
- ENDRA Life Sciences Inc. earnings
- ENDRA Life Sciences Inc. dividends
- ENDRA Life Sciences Inc. valuation
- ENDRA Life Sciences Inc. ownership and insiders
- ENDRA Life Sciences Inc. peers
Figures from ENDRA Life Sciences Inc.'s filings with the U.S. SEC, standardised automatically; prices are end-of-day closes. Not financial advice.